Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by AlfredSisleyon Nov 28, 2020 4:45pm
184 Views
Post# 31995371

RE:RE:DR DR - PART TIME CEO?

RE:RE:DR DR - PART TIME CEO?There is nothing petty or unsubstantiated about this.

1 person holding 2 CEO roles - By definition neither can be full-time, especially considering how active her other company has been on the partnering front over the last few months (one of the reasons she was brought on).

Perhaps her role at Bioasis does not require singificant amount of time at present, however, DRDR has been consistent about her anticpation of deals and data in the short term.

I believe one could reasonably assume that the day-to-day operations will only get busier as the company expands it's reach (Licensing, Partnering, R&D, Trials, etc..), which begs the question of why take on more responsibility ahead of this? 

Not to mention that there could potentially be some overlap between the 2 companies in the oncology space.

It's true that DRDR has a played an integral part in turning this ship around, brought money in, cut spending, and charted a course forward.

My post was meant only to highlight the poor optics of this.

This could very well be a non-event, I would be curious to know what some of the more vocal shareholders think of this?



Alfred 




<< Previous
Bullboard Posts
Next >>